217 related articles for article (PubMed ID: 35835997)
21. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.
Schmaelter AK; Labopin M; Socié G; Itälä-Remes M; Blaise D; Yakoub-Agha I; Forcade E; Cornelissen J; Ganser A; Beelen D; Labussière-Wallet H; Passweg J; Savani BN; Schmid C; Nagler A; Mohty M
Blood Cancer J; 2020 Mar; 10(3):26. PubMed ID: 32127519
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
[TBL] [Abstract][Full Text] [Related]
23. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
24. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
25. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
26. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
Murdock HM; Kim HT; Denlinger N; Vachhani P; Hambley B; Manning BS; Gier S; Cho C; Tsai HK; McCurdy S; Ho VT; Koreth J; Soiffer RJ; Ritz J; Carroll MP; Vasu S; Perales MA; Wang ES; Gondek LP; Devine S; Alyea EP; Lindsley RC; Gibson CJ
Blood; 2022 Jun; 139(24):3546-3557. PubMed ID: 35286378
[TBL] [Abstract][Full Text] [Related]
27. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT).
Maffini E; Labopin M; Blaise D; Ciceri F; Gülbas Z; Deconinck E; Leblond V; Chevallier P; Sociè G; Araujo MC; Koc Y; Savani BN; Gorin NC; Lanza F; Nagler A; Mohty M
Am J Hematol; 2020 Aug; 95(8):892-899. PubMed ID: 32303111
[TBL] [Abstract][Full Text] [Related]
28. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
29. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
Konuma T; Kondo T; Masuko M; Shimizu H; Shiratori S; Fukuda T; Kato J; Sawa M; Ozawa Y; Ota S; Uchida N; Kanda Y; Kako S; Fujisawa S; Fukushima K; Ichinohe T; Atsuta Y; Yanada M;
Bone Marrow Transplant; 2021 Nov; 56(11):2779-2787. PubMed ID: 34272486
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
[TBL] [Abstract][Full Text] [Related]
32. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron F; Nagler A; Galimard JE; Sanz J; Versluis J; Forcade E; Chevallier P; Sirvent A; Anthias C; Kuball J; Furst S; Rambaldi A; Sierra J; von dem Borne PA; Gallego Hernanz MP; Cluzeau T; Robinson S; Raiola AM; Labussière-Wallet H; Byrne JL; Malfuson JV; Ruggeri A; Mohty M; Ciceri F
Br J Haematol; 2024 Jan; 204(1):250-259. PubMed ID: 37784256
[TBL] [Abstract][Full Text] [Related]
33. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
34. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.
Gatwood KS; Labopin M; Savani BN; Finke J; Socie G; Beelen D; Yakoub-Agha I; Chevallier P; Ganser A; Blaise D; Milpied N; Bruno L; Mailhol A; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Jan; 55(1):224-232. PubMed ID: 31527819
[TBL] [Abstract][Full Text] [Related]
35. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
Walter RB; Gyurkocza B; Storer BE; Godwin CD; Pagel JM; Buckley SA; Sorror ML; Wood BL; Storb R; Appelbaum FR; Sandmaier BM
Leukemia; 2015 Jan; 29(1):137-44. PubMed ID: 24888275
[TBL] [Abstract][Full Text] [Related]
36. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
37. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
38. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
[TBL] [Abstract][Full Text] [Related]
39. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
40. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
